Biotech Firms Seek OK for Psoriasis Drug
- Share via
Genentech Inc. and Xoma Ltd. said they have asked U.S. regulators to approve Raptiva, an experimental treatment for moderate to severe psoriasis.
Raptiva, a monoclonal antibody given weekly by injection, reduced psoriasis by at least 75% in some 61% of patients taking it for a year in clinical trials.
Biogen Inc. is awaiting approval for its own experimental psoriasis treatment, Amevive. And Johnson & Johnson and Amgen Inc. plan to treat the skin disorder using their respective drugs Remicade and Enbrel, which already are approved for arthritis.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
